Center Profile

Share QR code Edit Profile

Schiff Center for Liver Diseases Contact information

Director:

Eugene Schiff

+1 (305) 2434615

eschiff@miami.edu

View:

Select
All (all in one) Mission Funded Research Websites Contact

All
Mission
Funded Research
Websites
Contact

Mission

To cure liver disease through innovative research, effective treatment and expert medical education.

Research Terms

Liver Diseases

Funded Research

These projects reflect the research conducted by the center experts.

End

Title

07-2019

WORK ORDER- PROTOCOL D35603- EXTERNAL EVALUATION TRIAL PROTOCOL FOR VITROS IMMUNODIAGNOSTI WORK ORDER- PROTOCOL D35603- EXTERNAL EVALUATION TRIAL PROTOCOL FOR VITROS IMMUNODIAGNOSTI

10-2018

COLLECTION OF PLASMA AND SERUM SAMPLES FROM INDIVIDUALS INITIATING THERAPY WITH SOFOSBUVIR COLLECTION OF PLASMA AND SERUM SAMPLES FROM INDIVIDUALS INITIATING THERAPY WITH SOFOSBUVIR

10-2018

COLLECTION OF PLASMA SAMPLES FROM INDIVIDUALS INITIATING THERAPY WITH ENTECAVIR OR TENOFOV COLLECTION OF PLASMA SAMPLES FROM INDIVIDUALS INITIATING THERAPY WITH ENTECAVIR OR TENOFOV

05-2018

PROTOCOL TMC435HPC3017: A PHASE 3, MULTICENTER, RANDOMIZED,OPEN-LABEL STUDY TO INVESTIGAT PROTOCOL TMC435HPC3017: A PHASE 3, MULTICENTER, RANDOMIZED,OPEN-LABEL STUDY TO INVESTIGAT

05-2018

PROTOCOL TMC435HPC3018: A PHASE 3, MULTICENTER, OPEN-LABEL,SINGLE-ARM STUDY TO INVESTIGAT PROTOCOL TMC435HPC3018: A PHASE 3, MULTICENTER, OPEN-LABEL,SINGLE-ARM STUDY TO INVESTIGAT

04-2018

RAPID DIAGNOSTIC TESTS CLINICAL TRIAL PROTOCOL: Multiplo Rapid Anti-HIV 1/2, Anti-HBc and Anti-HCV test for serum and plasma, finger stick and venous whole blood and Reveal Rapid Hepatitis B Surface Antigen test for serum and plasma, finger stick and ven RAPID DIAGNOSTIC TESTS CLINICAL TRIAL PROTOCOL: Multiplo Rapid Anti-HIV 1/2, Anti-HBc and Anti-HCV test for serum and plasma, finger stick and venous whole blood and Reveal Rapid Hepatitis B Surface Antigen test for serum and plasma, finger stick and ven

10-2017

SPECIMEN ACQUISITION FOR HEPATITIS EVALUATIONS STUDY NO. CIM RD001455 SPECIMEN ACQUISITION FOR HEPATITIS EVALUATIONS STUDY NO. CIM RD001455

09-2017

CIM RD001453 PERFORMANCE EVALUATION OF ELECSYS ANTI-HCV II IMMUNOASSAY AND PRECICONTROLS O CIM RD001453 PERFORMANCE EVALUATION OF ELECSYS ANTI-HCV II IMMUNOASSAY AND PRECICONTROLS O

05-2017

THE COLLECTION OF WHOLE BLOOD SPECIMENS FROM PATIENTS PRESENTING WITH CLINICAL SIGNS AND S THE COLLECTION OF WHOLE BLOOD SPECIMENS FROM PATIENTS PRESENTING WITH CLINICAL SIGNS AND S

02-2017

RANDOMIZED, OBSERVATIONAL STUDY OF THE ENTERCAVIR TO ASSESSLONG-TERM OUTCOMES ASSOCIATED RANDOMIZED, OBSERVATIONAL STUDY OF THE ENTERCAVIR TO ASSESSLONG-TERM OUTCOMES ASSOCIATED

01-2017

STUDY NO. CIM RD001452 - PERFORMANCE EVALUATION OF ELECYS HBSAGII IMMUNOASSAY, ELECYS HBSA STUDY NO. CIM RD001452 - PERFORMANCE EVALUATION OF ELECYS HBSAGII IMMUNOASSAY, ELECYS HBSA

01-2017

HEPATITIS C THERAPEUTIC REGISTRY AND RESEARCH NETWORK ("HCV-TARGET") HEPATITIS C THERAPEUTIC REGISTRY AND RESEARCH NETWORK ("HCV-TARGET")

12-2016

Rapid Diagnostics for HIV and Hepatitis: Multiplo HBc/HIV/HCV and Reveal HBsAg Rapid Diagnostics for HIV and Hepatitis: Multiplo HBc/HIV/HCV and Reveal HBsAg

12-2016

THE DETECTION OF HBV DNA AND HCV RNA AND DETERMINATION OF GENOTYPES IN WHOLE BLOOD OBTAINE THE DETECTION OF HBV DNA AND HCV RNA AND DETERMINATION OF GENOTYPES IN WHOLE BLOOD OBTAINE

11-2016

ROCHE ELECSYS SYPHILIS ASSAY EVALUATION TRIAL-CIM RD001681 ROCHE ELECSYS SYPHILIS ASSAY EVALUATION TRIAL-CIM RD001681

10-2016

Protocol: GS-US-337-0102 A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks inTreatment-Naïve Subjects with Chronic Genotype 1 HCV Infec Protocol: GS-US-337-0102 A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks inTreatment-Naïve Subjects with Chronic Genotype 1 HCV Infec

07-2016

OPTIMAL Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Educational Program (Protocol CLDF-MER-001-00) OPTIMAL Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Educational Program (Protocol CLDF-MER-001-00)

05-2016

Protocl GS-US-174-0149: A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon a-2a (Pegasys) versus Standard of Care Tenofovir D Protocl GS-US-174-0149: A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon a-2a (Pegasys) versus Standard of Care Tenofovir D

03-2016

Protocol GS-US-196-0140: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys) and Ribavirin (RBV, Copegus) Wi Protocol GS-US-196-0140: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys) and Ribavirin (RBV, Copegus) Wi

03-2016

Protocol P7977-1231: A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naive Patients with Chr Protocol P7977-1231: A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naive Patients with Chr

03-2016

Protocol NP27946: Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Ritonavir-Boosted DANOPREVIR in Combination with Peginterferon Alfa-2a Plus Ribavirin in Treatment-Naive Patients and with addition of RO5024048 in Previ Protocol NP27946: Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Ritonavir-Boosted DANOPREVIR in Combination with Peginterferon Alfa-2a Plus Ribavirin in Treatment-Naive Patients and with addition of RO5024048 in Previ

01-2016

GS-US-337-0123- A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have Advanced Liver Disease or are Post-Live GS-US-337-0123- A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have Advanced Liver Disease or are Post-Live

11-2015

Protocol P2938-0721:An International, Multi-center, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Administratin of Regimens Containing PSI-352938, PSI-7977, and Ribavirin in Patients with Ch Protocol P2938-0721:An International, Multi-center, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Administratin of Regimens Containing PSI-352938, PSI-7977, and Ribavirin in Patients with Ch

10-2015

Protocol GS-US-337-0108: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 8 Weeks Ribavirin and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Tre Protocol GS-US-337-0108: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 8 Weeks Ribavirin and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Tre

10-2015

Protocol GS-US-342-0109: A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment Experienced Subjects with Chronic HCV Infection Protocol GS-US-342-0109: A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment Experienced Subjects with Chronic HCV Infection

10-2015

GS-US-337-1118: An Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin For 12 Weeks In Chronic Genotype 1 HCV Infected Subjects Who Participated In A Prior Gilead-Sponsored HCV Tre GS-US-337-1118: An Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin For 12 Weeks In Chronic Genotype 1 HCV Infected Subjects Who Participated In A Prior Gilead-Sponsored HCV Tre

10-2015

A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naïve Subjects with Chronic HCV Infection A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naïve Subjects with Chronic HCV Infection

04-2015

Protocol ANA598-505: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of ANA598 Administered with Pegylated Interferon and Ribavirin in Genotype 1 Patients with Chronic Hepatitis C Infection. Protocol ANA598-505: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of ANA598 Administered with Pegylated Interferon and Ribavirin in Genotype 1 Patients with Chronic Hepatitis C Infection.

02-2015

Protocol CTS-1027-05: A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV -Responders. Protocol CTS-1027-05: A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV -Responders.

09-2014

EXTEND: A 3-Year, Virology Follow-up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies. EXTEND: A 3-Year, Virology Follow-up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies.

08-2014

Protocol TG4040.02: A Phase II Randomized, Multicenter, Open-Label Study of TG4040 (MVA-HCV) in combination with Pegylated Interferon Alfa-2A and Ribavirin versus Pegylated Interferon Alfa-2A and Ribavirin in Treatment-Naive Patients with Chronic Genotype Protocol TG4040.02: A Phase II Randomized, Multicenter, Open-Label Study of TG4040 (MVA-HCV) in combination with Pegylated Interferon Alfa-2A and Ribavirin versus Pegylated Interferon Alfa-2A and Ribavirin in Treatment-Naive Patients with Chronic Genotype

07-2014

Specimen Acquisition from Individuals with a Chronic HBV Infection. Specimen Acquisition from Individuals with a Chronic HBV Infection.

06-2014

AVIDA CENTAUR CP HBeAg AND ANTI-HBE MIGRATION STUDIES AVIDA CENTAUR CP HBeAg AND ANTI-HBE MIGRATION STUDIES

06-2014

P05216: A PHASE 3, SAFETY AND EFFICACY STUDY OF BOCEPREVIRIN PREVIOUSLY UNTREATED SUBJEC P05216: A PHASE 3, SAFETY AND EFFICACY STUDY OF BOCEPREVIRIN PREVIOUSLY UNTREATED SUBJEC

05-2014

Subject Enrolment and Sample Acquisition Protocol for the ADVIA Centaur ELF Test Validation Studies Subject Enrolment and Sample Acquisition Protocol for the ADVIA Centaur ELF Test Validation Studies

05-2014

Type of Clinical Research Study: A phase II, multi-center, randomized, open-label, active-control, dose-ranging study of interferon ?-2b given via continuous subcutaneous infusion in subjects with Hepatitis C Virus genotype 1 infection (Medtronic) Type of Clinical Research Study: A phase II, multi-center, randomized, open-label, active-control, dose-ranging study of interferon ?-2b given via continuous subcutaneous infusion in subjects with Hepatitis C Virus genotype 1 infection (Medtronic)

04-2014

NOV205-C201 A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment with Pegylated Interferon plus Ribavirin NOV205-C201 A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment with Pegylated Interferon plus Ribavirin

03-2014

LONG-TERM FOLLOW UP OF SUBJECT IN A PHASE 2 OR 3 CLINICAL TRIALS IN WHICH SCH 503034 WAS ADMINISTERED FOR TREATMENT OF CRONIC HEPATITIS C LONG-TERM FOLLOW UP OF SUBJECT IN A PHASE 2 OR 3 CLINICAL TRIALS IN WHICH SCH 503034 WAS ADMINISTERED FOR TREATMENT OF CRONIC HEPATITIS C

03-2014

Protocol VX-950-TiDP24-C219: An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) for subjects from the control group of the VX-950-TiDP24-C216 trial who failed therapy Protocol VX-950-TiDP24-C219: An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) for subjects from the control group of the VX-950-TiDP24-C216 trial who failed therapy

10-2013

ANA598-504: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Trial of the Safety, Efficacy, and Pharmacokinetics of ANA598 Administered with Pegylated Interferon and Ribavirin in Treatment-Naïve Genotype 1 Patients with Ch ANA598-504: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Trial of the Safety, Efficacy, and Pharmacokinetics of ANA598 Administered with Pegylated Interferon and Ribavirin in Treatment-Naïve Genotype 1 Patients with Ch

10-2013

Protocol GS-US-248-0131: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subjects with Chronic Genotype 1a or 1b Protocol GS-US-248-0131: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subjects with Chronic Genotype 1a or 1b

10-2013

Protocol GS-US-248-0132: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects with Chronic Protocol GS-US-248-0132: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects with Chronic

10-2013

Protocol GS-US-256-0124: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 in Combination with GS-9256 or GS-9451 or Tegobuvir with Peginterferon Alfa 2a and Ribavirin in Treatment Experienced S Protocol GS-US-256-0124: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 in Combination with GS-9256 or GS-9451 or Tegobuvir with Peginterferon Alfa 2a and Ribavirin in Treatment Experienced S

10-2013

Protocol GS-US-256-0148: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treatment Naive Subjects with Chronic Protocol GS-US-256-0148: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treatment Naive Subjects with Chronic

08-2013

Performance Evaluation of Elecsys® Anti-HBc IgM Immunoassay and PreciControls on Modular E170, cobas® e411 and cobas® e601 Analyzers Performance Evaluation of Elecsys® Anti-HBc IgM Immunoassay and PreciControls on Modular E170, cobas® e411 and cobas® e601 Analyzers

07-2013

Protocol 009-04: A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly with Pegylated Interferon and Ribavirin in Treatment-Experienced Patient Protocol 009-04: A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly with Pegylated Interferon and Ribavirin in Treatment-Experienced Patient

07-2013

PROTOCOL 009-04: A PHASE II RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, T PROTOCOL 009-04: A PHASE II RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, T

05-2013

Use of Beckman Coulter's Access Immunoassay System Assays for Hepatitis Viruses for the Diagnosis of Hepatitis Infection and Disease: Subject Enrollment Protocol #HBV-01-08 Use of Beckman Coulter's Access Immunoassay System Assays for Hepatitis Viruses for the Diagnosis of Hepatitis Infection and Disease: Subject Enrollment Protocol #HBV-01-08

04-2013

(Sample Collection) Performance Evaluation of Elecsys Anti-HCV Assay on cobas e 411, cobas e 601 and Modular Analytics E170 Analyzers - Protocol CIM RD000646 (X08I001) (Sample Collection) Performance Evaluation of Elecsys Anti-HCV Assay on cobas e 411, cobas e 601 and Modular Analytics E170 Analyzers - Protocol CIM RD000646 (X08I001)

01-2013

P05104: A Study of SCH 900518 in Previously Untreated Subjects with Genotype 1 Chronic Hepatitis C P05104: A Study of SCH 900518 in Previously Untreated Subjects with Genotype 1 Chronic Hepatitis C

01-2013

P05101: Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin A Phase 3 Safety and Efficacy Study P05101: Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin A Phase 3 Safety and Efficacy Study

01-2013

SCI-SCV-HCV-P2-001: A Phase 2, Multicenter, Multidose, Open-Label Study to Evaluate the Safety and Immunomodulatory Effects of SCV-07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Genotype 1 Chronic Hepatitis C who Have Re SCI-SCV-HCV-P2-001: A Phase 2, Multicenter, Multidose, Open-Label Study to Evaluate the Safety and Immunomodulatory Effects of SCV-07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Genotype 1 Chronic Hepatitis C who Have Re

12-2012

VX-950-TiDP24: A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) in subjects with chronic genotype 1 h VX-950-TiDP24: A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) in subjects with chronic genotype 1 h

12-2012

VX07-950-108: A Phase 3 Study of 2 Dose Regimens of telaprevir in Combination With Peginterferon Alfa 2a (Pegasys) and Ribavirin (Copegus) in Treatment Naïve Subjects with Genotype 1 Chronic Hepatitis C VX07-950-108: A Phase 3 Study of 2 Dose Regimens of telaprevir in Combination With Peginterferon Alfa 2a (Pegasys) and Ribavirin (Copegus) in Treatment Naïve Subjects with Genotype 1 Chronic Hepatitis C

11-2012

P03523:SAFETY AND EFFICACY STUDY OF SCH 50304 IN PREVIOUSLY UNTREATED SUBJECTS WITH CHRONIC HEPATITIS C INFECTED WITH GENOTYPE 1 P03523:SAFETY AND EFFICACY STUDY OF SCH 50304 IN PREVIOUSLY UNTREATED SUBJECTS WITH CHRONIC HEPATITIS C INFECTED WITH GENOTYPE 1

11-2012

VITROS HBeAg/Anti-Hbe: Hepatitis High Risk Sample collection Protocol (eProst ID: 20090005) VITROS HBeAg/Anti-Hbe: Hepatitis High Risk Sample collection Protocol (eProst ID: 20090005)

11-2012

CLINICAL TESTING PROTOCOL: THE VITROS HBeAg ASSAY AND THE VITROS ANTI-HBE ASSAY AMMENDMENT 2 CLINICAL TESTING PROTOCOL: THE VITROS HBeAg ASSAY AND THE VITROS ANTI-HBE ASSAY AMMENDMENT 2

10-2012

A PHASE 2, DOUBLE BLIND, MULTI CENTER, RANDOMIZED STUDY COMPARING TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE PLUS TENOFOVIR DISOPROXIL FUMARATE, AND ENTOCAVIR IN THE TREATMENT OF CHRONIC HEPATITIS B SUBJECTS WITH DECOMPENSATED LIVER DISEASE AND IN THE P A PHASE 2, DOUBLE BLIND, MULTI CENTER, RANDOMIZED STUDY COMPARING TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE PLUS TENOFOVIR DISOPROXIL FUMARATE, AND ENTOCAVIR IN THE TREATMENT OF CHRONIC HEPATITIS B SUBJECTS WITH DECOMPENSATED LIVER DISEASE AND IN THE P

09-2012

ADVIA CENTAUR SYSTEMS HIV AG/AB COMBO (CHIV) ASSAY CLINICALPROTOCOL. ADVIA CENTAUR SYSTEMS HIV AG/AB COMBO (CHIV) ASSAY CLINICALPROTOCOL.

07-2012

GS-US-196-0103: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING GS-US-196-0103: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING

12-2011

A PHASE 2 RANDOMIZED OPEN LABEL MULTI-CENTER THERAPEUTIC TRIAL OF EFFICACY, IMMUNOGENICITY A PHASE 2 RANDOMIZED OPEN LABEL MULTI-CENTER THERAPEUTIC TRIAL OF EFFICACY, IMMUNOGENICITY

10-2011

(TESTING) PERFORMANCE EVALUATION OF ELECSYS ANTI-HCV ASSAY ON COBAS E 411, COBAS E 601 AND (TESTING) PERFORMANCE EVALUATION OF ELECSYS ANTI-HCV ASSAY ON COBAS E 411, COBAS E 601 AND

09-2011

OQ-HCV-WB-16: CLINICAL INVESTIGATION TO EVALUATE THE PERFORMANCE OF THE ORAQUICK RAPID HC OQ-HCV-WB-16: CLINICAL INVESTIGATION TO EVALUATE THE PERFORMANCE OF THE ORAQUICK RAPID HC

09-2011

OQ-HCV-OF-FS-17: CLINICAL INVESTIGATION TO EVALUATE THE PERFORMANCE OF THE ORAQUICK% RAPI OQ-HCV-OF-FS-17: CLINICAL INVESTIGATION TO EVALUATE THE PERFORMANCE OF THE ORAQUICK% RAPI

06-2011

GS-US-227-0106: A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED GS-US-227-0106: A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED

06-2011

ENROLLMENT/SAMPLE ACQUISITION PROTOCOL FOR SIEMENS PLATFORMHEPATITIS ASSAYS. ENROLLMENT/SAMPLE ACQUISITION PROTOCOL FOR SIEMENS PLATFORMHEPATITIS ASSAYS.

05-2011

AN OPEN LABEL RANDOMIZED 5ARM PARALLEL GROUP STUDY OF THE EFFECTS ON VIRAL KINETICS SAFTEY AN OPEN LABEL RANDOMIZED 5ARM PARALLEL GROUP STUDY OF THE EFFECTS ON VIRAL KINETICS SAFTEY

04-2011

CLINICAL INVESTIGATION TO EVALUATE THE PERFORMANCE THE ORAQUICK RAPID HCV ANTIBODY TEST CLINICAL INVESTIGATION TO EVALUATE THE PERFORMANCE THE ORAQUICK RAPID HCV ANTIBODY TEST

Websites

https://med.miami.edu/centers-and-institutes/schiff-center-for-liver-diseases

Directors

Eugene Schiff

+1 (305) 2434615

eschiff@miami.edu

Call Email

Contact Information

Director

eschiff@miami.edu

+1 (305) 2434615

Center

1500 NW 12 Ave
Miami, FL 33136

(305) 243-4615

Profile QR code

What is this?

Schiff Center for Liver Diseases Contact information

Mission

Research Terms

Funded Research

Websites

Directors

Contact Information

About

Discover

Connect

Keyword Search

Browse by STEM